Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies : Episode 5
Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.
EP: 1.Indication and Practical Utilization of IV and Subcutaneous Biologics
EP: 2.Key Consideration and Concerns Around IV and Subcutaneous Biologic Use
EP: 3.Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
EP: 4.Key Patient Factors in Determining an Optimal Biologic Therapy
Now Viewing
EP: 5.Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
EP: 6.Future Predictions for Intravenous and Subcutaneous Biologics
EP: 7.Overall Experience With Intravenous Biologics
EP: 8.Clinical Insights With Subcutaneous Biologics
EP: 9.Innovations Associated With IV Biologics
EP: 10.Exciting Developments With Subcutaneous Biologics
EP: 11.Positioning Intravenous and Subcutaneous Biologics
EP: 12.Adherence With Intravenous Biologics
EP: 13.Billing With Intravenous and Subcutaneous Therapies
EP: 14.Evaluating Efficacy Between Intravenous and Subcutaneous Biologics
EP: 15.Cost Considerations With Intravenous and Subcutaneous Biologics
EP: 16.Patient Experience With Intravenous and Subcutaneous Therapies
Video content above is prompted by the following questions:
- How do you evaluate the costs between IV vs. subcutaneous therapies when deciding which route of administration to use in patients?
- Patient perspectives have been analyzed in those taking IV biologics for rheumatoid arthritis. What did the results show, and do they factor into your treatment decisions?
Recent Videos
Related Content
